Next Article in Journal
Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcitabine Designed to Deliver Prolonged Systemic Exposure
Next Article in Special Issue
Delivery of Cancer Therapeutics Using Nanotechnology
Previous Article in Journal
Design, Synthesis and in Vitro Degradation of a Novel Co-Drug for the Treatment of Psoriasis
Previous Article in Special Issue
From Molecular to Nanotechnology Strategies for Delivery of Neurotrophins: Emphasis on Brain-Derived Neurotrophic Factor (BDNF)
Article Menu

Export Article

Open AccessArticle
Pharmaceutics 2013, 5(2), 246-260; doi:10.3390/pharmaceutics5020246

Development of a Novel Lipophilic, Magnetic Nanoparticle for in Vivo Drug Delivery

Section of Neurobiology, Biomedicine, Department of Health Science and Technology, Aalborg University, Fr. Bajers Vej 3B, 1.216, DK-9220 Aalborg East, Denmark
*
Author to whom correspondence should be addressed.
Received: 25 February 2013 / Revised: 2 April 2013 / Accepted: 12 April 2013 / Published: 23 April 2013
(This article belongs to the Special Issue Drug Delivery Using Nanotechnology)
View Full-Text   |   Download PDF [4609 KB, uploaded 23 April 2013]   |  

Abstract

The aim of the present study was to evaluate the transfection potential of chitosan-coated, green-fluorescent magnetic nanoparticles (MNPs) (chi-MNPs) after encapsulation inside polyethylglycol (PEG)ylated liposomes that produced lipid-encapsulated chitosan-coated MNPs (lip-MNPs), and also to evaluate how these particles would distribute in vivo after systemic injection. The transfection potential of both chi-MNPs and lip-MNPs was evaluated in vitro in rat brain endothelial 4 (RBE4) cells with and without applying a magnetic field. Subsequently, the MNPs were evaluated in vivo in young rats. The in vitro investigations revealed that the application of a magnetic field resulted in an increased cellular uptake of the particles. The lip-MNPs were able to transfect the RBE4 cells with an incidence of approximately 20% of a commercial transfection agent. The in vivo distribution studies revealed that lip-MNPs had superior pharmacokinetic properties due to evasion of the RES, including hepatic Kuppfer cells and macrophages in the spleen. In conclusion, we were able to design a novel lipid-encapsulated MNP with the ability to carry genetic material, with favorable pharmacokinetic properties, and under the influence of a magnetic field with the capability to mediate transfection in vitro. View Full-Text
Keywords: blood-brain barrier; endothelium; magnetofection; magnetic field; nanoparticle; transfection blood-brain barrier; endothelium; magnetofection; magnetic field; nanoparticle; transfection
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Linemann, T.; Thomsen, L.B.; Jardin, K.G.; Laursen, J.C.; Jensen, J.B.; Lichota, J.; Moos, T. Development of a Novel Lipophilic, Magnetic Nanoparticle for in Vivo Drug Delivery. Pharmaceutics 2013, 5, 246-260.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top